Brokerages at the Wall Street Stock Exchange have predicted that the stocks of BCRX would be putting up a sales sum of $14.72 million for the current quarter. According to reports, four of the investment analysts have already provided estimates into the earnings of the company- with the ranges fixed from $3.20 million to $29.99 million. BCRX also posted a sum of $39.73 million the previous year- so this should be indicative of a negative annual growth rate of about 62.9%. The company will be issuing its next quarterly report on the 4th of March.
The Quarterly Estimate of BCRX
BCRX previously updated its earnings report on the 5th of November. The biotech firm reported an EPS of $0.26, which was more than the consensus estimate reported at $0.25. The company has a -233.45% net margin, with a -328.70% return on its equity. The revenue for the quarter was $6.10 million- more than the $4.31 million consensus estimate.
There have been quite a few brokerage firms that have commented on the stocks of BCRX. HC Wainwright has already increased the shares of the company from a sum of $13 to $14, along with a rating of buy in a 7th December research report. Zacks also gave the company a rating of hold after it had previously fixed up a rating of sell in a 6th January research report.
TheStreet has also increased the shares of the company from a rating of d+ to c- in a 13th January research report. Evercore ISI decided to put up a rating of outperform, along with a $12 price target on the company. In the end, the Royal Bank of Canada also followed the bandwagon- having increased the price target from $7 to $9, with a sector perform- in a 22nd January research report.
The stocks of BCRX traded on Friday at $9.65. The moving average over 50 days is $8.31, while the moving average over 200-days is $5.35. The current ratio of the company is 1.45, while it also enjoys a 1.40 quick ratio. The market cap of BCRX has been set at $1.70 billion.
